PMC:7361216 / 10-273 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":199,"end":202},"obj":"Body_part"},{"id":"T3","span":{"begin":227,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62977"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":227,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":30,"end":48},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":23,"end":24},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":58,"end":59},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":74,"end":75},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":105,"end":106},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":240,"end":247},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T1","span":{"begin":41,"end":48},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T1","span":{"begin":129,"end":137},"obj":"Species"}],"attributes":[{"id":"A1","pred":"ncbi_taxonomy_id","subj":"T1","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T1","span":{"begin":227,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"4","span":{"begin":30,"end":48},"obj":"Disease"},{"id":"3","span":{"begin":76,"end":88},"obj":"Chemical"},{"id":"5","span":{"begin":129,"end":137},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"pubann:denotes","subj":"4","obj":"MESH:D020271"},{"id":"A5","pred":"pubann:denotes","subj":"5","obj":"MESH:C000657245"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T1","span":{"begin":195,"end":198},"obj":"Protein"}],"attributes":[{"id":"A1","pred":"uniprot_id","subj":"T1","obj":"https://www.uniprot.org/uniprot/Q567S4"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T2","span":{"begin":199,"end":202},"obj":"Body_part"},{"id":"T3","span":{"begin":227,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma62977"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T1","span":{"begin":30,"end":48},"obj":"Disease"},{"id":"T2","span":{"begin":129,"end":137},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}

{"project":"LitCovid-PubTator","denotations":[{"id":"3","span":{"begin":76,"end":88},"obj":"Chemical"},{"id":"4","span":{"begin":30,"end":48},"obj":"Disease"},{"id":"5","span":{"begin":129,"end":137},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"MESH:D020271"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD‐19\nAn Editorial Highlight for “Selective inhibition of anti‐MAG IgM autoantibody binding to myelin by an antigen specific glycop"}